Here are three things to know.
1. The company offers:
- BioBurst Renu, a line of wound protection and healing products derived from placental tissue
- BioBurst Fluid, a cellular suspension designed to aid in the bone consolidation process
- BioBurst Captiv, a line of bone allografts
- BioBurst Rejuv, an umbilical cord blood-derived cellular allograft for soft tissue regeneration and ligament condition treatment
2. Chris Jones founded Burst Biologics in 2010 to focus on research and development in the field of regenerative medicine.
3. In 2017, Burst Biologics began a multi-center prospective clinical study of spinal fusion patients using BioBurst Fluid.
More articles on biologics:
Patients duped by non-FDA approved stem cell marketing: 8 things to know
Crowdfunding for stem cell treatments may spread misinformation: 4 insights
4 things to know about NuVasive’s AttraX Putty
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
